DelveInsight’s “Low Grade Glioma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Low Grade Glioma, historical and forecasted epidemiology as well as the Low Grade Glioma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Low Grade Glioma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Low Grade Glioma Market Forecast
Some of the key facts of the Low Grade Glioma Market Report:
-
The Low Grade Glioma market size was valued ~USD 990 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In January 2025, The FDA has authorized the use of FoundationOne CDx as a companion diagnostic for tovorafenib in treating patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma (pLGG) that carries a BRAF fusion, rearrangement, or V600 mutation. Tovorafenib had earlier received accelerated approval from the FDA in April 2024 for managing relapsed or refractory BRAF-altered pLGG, the most prevalent brain tumor in children.
-
In April 2024, Denovo Biopharma LLC (Denovo), a leader in precision medicine for innovative therapy development, announced that the California Institute for Regenerative Medicine (CIRM) has granted $11.8 million to advance DB107. This late-stage gene therapy, guided by Denovo's DGM7™ biomarker, targets high-grade glioma (HGG), including glioblastoma (GBM), a malignant brain cancer. The grant supports Dr. Noriyuki Kasahara, MD, PhD, at the University of California San Francisco (UCSF), along with investigators from California universities, to conduct a Phase 1/2 clinical trial of DB107 in newly diagnosed HGG patients.
-
In 2023, the total market size for low-grade glioma in the United States was projected to exceed USD 550 million, with anticipated growth throughout the forecast period from 2024 to 2034.
-
In 2022, the market size of low-grade glioma (LGG) in Japan is below USD 100 million, with an anticipated increase during the forecast period from 2024 to 2034.
-
In April 2024, Day One Biopharmaceuticals revealed that OJEMDA (tovorafenib) has received FDA approval under accelerated approval for patients aged 6 months and older diagnosed with relapsed or refractory pediatric low-grade glioma (pLGG) that contains a BRAF fusion or rearrangement, or a BRAF V600 mutation.
-
The US FDA has accepted and given priority review status to Servier's new drug application for VORASIDENIB, intended for the treatment of IDH-mutant diffuse glioma. The Prescription Drug User Fee Act (PDUFA) action date is scheduled for August 20, 2024.
-
In 2023, the total number of incident cases of low-grade glioma in the seven major markets (7MM) exceeded 9,000.
-
In 2023, among the seven major markets (7MM), the United States reported the highest number of incident cases of low-grade glioma, with over 3700 cases. These figures are projected to rise during the forecast period.
-
Key Low Grade Glioma Companies: Novartis, Day One Biopharmaceuticals, Servier, Nuvation Bio, The Hospital for Sick Children, University of California, Day One Biopharmaceuticals, Daiichi Sankyo Co., Julie Krystal, Novartis, Servier, SpringWorks Therapeutics, AnHeart Therapeutics, Beigene, Helsinn, Forma Therapeutics, Hoffmann-La Roche, and others
-
Key Low Grade Glioma Therapies: TAFINLAR (dabrafenib) + MEKINIST (trametinib), OJEMDA (tovorafenib), Vorasidenib, Safusidenib/AB-218, Tovorafenib, Vinblastine, Everolimus, DAY101, DS-1001b, Mebendazole, dabrafenib, Vorasidenib, Mirdametinib, AB-218, BGB-290, Infigratinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, and others
-
The Low Grade Glioma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Low Grade Glioma pipeline products will significantly revolutionize the Low Grade Glioma market dynamics.
Low Grade Glioma Overview
Low-grade glioma is a type of brain tumor that originates from glial cells, which support and protect nerve cells in the brain. These tumors are typically slow-growing and less aggressive than high-grade gliomas. Symptoms may include headaches, seizures, or changes in cognitive function, depending on the tumor's location. Low-grade gliomas are often treated with surgery, radiation therapy, and sometimes chemotherapy. While they may remain stable for years, they can sometimes progress to higher-grade, more aggressive tumors, so ongoing monitoring is necessary.
Get a Free sample for the Low Grade Glioma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/low-grade-glioma-market
Low Grade Glioma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Low Grade Glioma Epidemiology Segmentation:
The Low Grade Glioma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Low Grade Glioma
-
Prevalent Cases of Low Grade Glioma by severity
-
Gender-specific Prevalence of Low Grade Glioma
-
Diagnosed Cases of Episodic and Chronic Low Grade Glioma
Download the report to understand which factors are driving Low Grade Glioma epidemiology trends @ Low Grade Glioma Epidemiology Forecast
Low Grade Glioma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Low Grade Glioma market or expected to get launched during the study period. The analysis covers Low Grade Glioma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Low Grade Glioma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Low Grade Glioma Therapies and Key Companies
-
TAFINLAR (dabrafenib) + MEKINIST (trametinib): Novartis
-
OJEMDA (tovorafenib): Day One Biopharmaceuticals
-
Vorasidenib: Servier
-
Safusidenib/AB-218: Nuvation Bio
-
Tovorafenib: Day One Biopharmaceuticals
-
Vinblastine: The Hospital for Sick Children
-
Everolimus: University of California
-
DAY101: Day One Biopharmaceuticals
-
DS-1001b: Daiichi Sankyo Co.
-
Mebendazole: Julie Krystal
-
dabrafenib: Novartis
-
Vorasidenib: Servier
-
Mirdametinib: SpringWorks Therapeutics
-
AB-218: AnHeart Therapeutics
-
BGB-290: Beigene
-
Infigratinib: Helsinn
-
FT-2102 (Olutasidenib): Forma Therapeutics
-
Vinblastine + Bevacizumab: Hoffmann-La Roche
Discover more about therapies set to grab major Low Grade Glioma market share @ Low Grade Glioma Treatment Landscape
Low Grade Glioma Market Strengths
-
Low Grade Glioma is a rare form is glioma; thus, companies developing treatment options for the same can possess several advantages like market exclusivities, premium pricing, subsidy for conducting trials, and several other benefits from the government bodies for R&D.
Low Grade Glioma Market Opportunities
-
Newer imaging techniques, such as MR spectroscopy (MRS) and positron emission tomography (PET) imaging, may improve the diagnostic potential, challenges exist in the ability for conventional MRI to distinguish between primary tumours versus metastases and CNS masses, and true progression versus pseudo progression.
Scope of the Low Grade Glioma Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Low Grade Glioma Companies: Novartis, Day One Biopharmaceuticals, Servier, Nuvation Bio, The Hospital for Sick Children, University of California, Day One Biopharmaceuticals, Daiichi Sankyo Co., Julie Krystal, Novartis, Servier, SpringWorks Therapeutics, AnHeart Therapeutics, Beigene, Helsinn, Forma Therapeutics, Hoffmann-La Roche, and others
-
Key Low Grade Glioma Therapies: TAFINLAR (dabrafenib) + MEKINIST (trametinib), OJEMDA (tovorafenib), Vorasidenib, Safusidenib/AB-218, Tovorafenib, Vinblastine, Everolimus, DAY101, DS-1001b, Mebendazole, dabrafenib, Vorasidenib, Mirdametinib, AB-218, BGB-290, Infigratinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, and others
-
Low Grade Glioma Therapeutic Assessment: Low Grade Glioma current marketed and Low Grade Glioma emerging therapies
-
Low Grade Glioma Market Dynamics: Low Grade Glioma market drivers and Low Grade Glioma market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Low Grade Glioma Unmet Needs, KOL’s views, Analyst’s views, Low Grade Glioma Market Access and Reimbursement
To know more about Low Grade Glioma companies working in the treatment market, visit @ Low Grade Glioma Clinical Trials and Therapeutic Assessment
Table of Contents
1. Low Grade Glioma Market Report Introduction
2. Executive Summary for Low Grade Glioma
3. SWOT analysis of Low Grade Glioma
4. Low Grade Glioma Patient Share (%) Overview at a Glance
5. Low Grade Glioma Market Overview at a Glance
6. Low Grade Glioma Disease Background and Overview
7. Low Grade Glioma Epidemiology and Patient Population
8. Country-Specific Patient Population of Low Grade Glioma
9. Low Grade Glioma Current Treatment and Medical Practices
10. Low Grade Glioma Unmet Needs
11. Low Grade Glioma Emerging Therapies
12. Low Grade Glioma Market Outlook
13. Country-Wise Low Grade Glioma Market Analysis (2020–2034)
14. Low Grade Glioma Market Access and Reimbursement of Therapies
15. Low Grade Glioma Market Drivers
16. Low Grade Glioma Market Barriers
17. Low Grade Glioma Appendix
18. Low Grade Glioma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
